Kimberly Manhard
Corporate Officer/Principal bei ACADIA PHARMACEUTICALS INC.
Profil
Kimberly J.
Manhard is currently the Director at Shoreline Biosciences, Inc. and Toragen, Inc. She is also an Independent Director at Inhibrx Biosciences, Inc. and a Trustee at The Fleet Science Center.
In her former positions, she served as the Director & Corporate Compliance Officer at Ardea Biosciences, Inc. from 2009 to 2016.
She was also an Independent Director at Inhibrx, Inc. from 2020 to 2024.
Additionally, she held the position of Executive VP-Drug Development at Heron Therapeutics, Inc. in 2023.
Ms. Manhard has a background in Regulatory Affairs, having worked as the Head-Regulatory Affairs at Bristol Myers Squibb Co. and Agouron Global Commercial Operations.
She was also a Vice President-Regulatory Affairs at Exelixis, Inc. from 2002 to 2003.
Ms. Manhard holds an undergraduate degree from the University of Florida.
Aktive Positionen von Kimberly Manhard
| Unternehmen | Position | Beginn |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 30.01.2024 |
| Fleet Science Center | Direktor/Vorstandsmitglied | - |
Shoreline Biosciences, Inc.
 Shoreline Biosciences, Inc. BiotechnologyHealth Technology Shoreline Biosciences, Inc. engages in biotechnology business activities. The company is headquartered in La Jolla, CA. | Direktor/Vorstandsmitglied | 19.05.2021 |
Toragen, Inc.
 Toragen, Inc. BiotechnologyHealth Technology Toragen, Inc. is a clinical-stage biotechnology company that is focused on developing treatments for HPV-induced cancers, starting with head and neck cancer. Toragen is based in San Diego, CA. The company is targeting the root cause of virally induced cancers. The company was founded by Andrew Sharabi and the CEO is Sandra I. Coufal. | Direktor/Vorstandsmitglied | 01.05.2020 |
Ehemalige bekannte Positionen von Kimberly Manhard
| Unternehmen | Position | Ende |
|---|---|---|
| INHIBRX, INC. | Direktor/Vorstandsmitglied | 30.05.2024 |
| HERON THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 21.02.2023 |
Ardea Biosciences, Inc.
 Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Geschäftsführer | 23.06.2009 |
| EXELIXIS, INC. | General Counsel | 01.01.2003 |
| G.H. Besselaar Associates | Corporate Officer/Principal | - |
Ausbildung von Kimberly Manhard
| University of Florida | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| HERON THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
| Agouron Global Commercial Operations | |
| G.H. Besselaar Associates | |
| Fleet Science Center | |
Inhibrx, Inc.
 Inhibrx, Inc. BiotechnologyHealth Technology Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA. | Health Technology |
Shoreline Biosciences, Inc.
Shoreline Biosciences, Inc. BiotechnologyHealth Technology Shoreline Biosciences, Inc. engages in biotechnology business activities. The company is headquartered in La Jolla, CA. | Health Technology |
Toragen, Inc.
Toragen, Inc. BiotechnologyHealth Technology Toragen, Inc. is a clinical-stage biotechnology company that is focused on developing treatments for HPV-induced cancers, starting with head and neck cancer. Toragen is based in San Diego, CA. The company is targeting the root cause of virally induced cancers. The company was founded by Andrew Sharabi and the CEO is Sandra I. Coufal. | Health Technology |
